New PET scan agent could spot bladder cancer earlier
NCT ID NCT04897763
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new imaging agent called 89Zr-girentuximab in 6 people with non-muscle-invasive bladder cancer. The goal was to see if it could safely and clearly show tumors on PET/CT scans. Researchers looked for uptake spots in the bladder and checked for side effects up to 30 days after injection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut de cancerologie de l'Ouest
Saint-Herblain, 44805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Bag-Like device pull bladder tumors out whole?
- Could a simple blood or urine test spot bladder cancer earlier?
- Can Pre-Surgery chemotherapy outsmart aggressive bladder cancer?
- Can heated chemotherapy beat bladder cancer without surgery?
- Bladder cancer: a new combo aims to avoid radical surgery
- Could a simple urine test spare bladder cancer patients from chemotherapy?